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Abstract. Novel drug excipients are required to achieve stable formulations of protein drug 
candidates. Synthetic glycopolymers have been shown in some cases to improve protein formulation 
stability, although their structure-function relationship remains unknown. Here we report the 
synthesis of linear or 4-arm star glycopolymers with different molecular topology and chemical 
composition, with mannose, galactose, arabinose, N-acetyl glucosamine, lactose and trehalose 
pendant units - and investigate their modulation of conformational stability and aggregation 
propensity of a model monoclonal antibody (mAb1). Mono-and di-saccharides with free reducing ends 
are not frequently utilised as protein stabilisers, due to potential reactivity with a protein’s amine 
groups. In this study this was circumvented through the use of a stable acetal linker connecting the 
polymer backbone to the sugar pendant residues, which made the latter virtually non-reactive with 
amines. The general destabilisation the antibody was determined as anunfolding transition 
temperature (Tm) of CH2 and Fab structural domains, and aggregation temperature (Tagg). The most 
prominent effect of the glycopolymers on a temperature induced stress in a low concentration 
solutions was a decrease in Tm and Tagg, regardless of sugar composition or glycopolymer topology - 
in contrast to the stabilising effect of the corresponding mono- and di-saccharide constituents. The 
exceptions of linear-lactose and star-trehalose glycopolymers, which increased Tm of the mAb Fab 
region and Tagg, however, highlights a more complex structure-function relationship. Accelerated 
stability studies of the high concentrated mAb solutions (50 mg mL-1) revealed that the increased 
glycopolymer concentrations generally decreased the mAb stability, as judged by the amount of mAb1 
‘monomer’ molecules in solution, with star- and linear-trehalose glycopolymers further generating 
visible aggregates. Interestingly the latter effect could not have been predicted from the Tm or Tagg 
experiments conducted at a low concentration regime. Taken together, the data demonstrate a 
complex interplay of sugar chemistry and molecular topology of the synthetic glycopolymers on their 
modulation of protein conformational stability and aggregation propensity. Solution concentration 
was also an important parameter contributing to the stability modulation, and suggests that the 
stabilising properties of a sugar as the mono- or di-saccharide cannot be extrapolated to the 
corresponding glycopolymers. 
 
Introduction 
Biopharmaceuticals are a large segment of the pharmaceutical industry, representing over 
40% of the products currently in the industrial R&D pipeline, with an estimated annual revenue 
of about $75 billion worldwide.1 Development of protein pharmaceuticals is challenging, with 
a number of hurdles that need to be overcome.2, 3 Most biotherapeutics can degrade at various 
stages of their preparation/utilisation - e.g. bioprocessing, storage and transport - hence 
requiring special precautions, such as controlled temperature and pH, and the addition of 
stabilising excipients.4-7 Amongst the physical instability pathways, protein aggregation is 
arguably the most common and often problematic, and can result from physical and/or 
chemical insults at all phases of the development process.2 The underlying challenge in protein 
formulation is to retain the native conformation of the biotherapeutic, which relies on a 
complex and often fragile network of intramolecular non-covalent interactions. These include 
ion pairing, H-bonding and other dipolar forces, π-effects, and van der Waals interactions, all 
of which can be affected by the physico-chemical conditions of the surrounding medium. Upon 
unfolding and subsequent irreversible aggregation, protein therapeutics may present reduced 
or even suppressed activity, decreased solubility, and altered immunogenicity.8 A number of 
strategies have been developed to address this issue, with variable success.9  
An important approach for stabilising protein formulations involves the use of excipients. 
These can be diverse in chemistry and function, and include salts, carbohydrates, proteins and 
polymers.10-13 Low molecular weight sugars - e.g. mono- or disaccharides - and polyols are 
important classes of protein stabilisers which can minimize both physical and chemical 
degradations pathways.14, 15 Although their mechanisms of stabilisation are not fully 
understood, the preferential exclusion/hydration hypothesis describes the exclusion of a sugar 
is excluded from the protein surface. In turn, this can thermodynamically favour the protein 
conformation with the smallest surface area (generally corresponding to its native state).16,17, 
18   
A recent study by Maynard and co-workers has shown that appropriately designed trehalose 
glycopolymers are superior to their isolated low molecular weight trehalose disaccharide 
components in their ability to help a model protein, lysozyme, to retain its enzymatic activity 
after stress stimuli, when.19 This pioneering work suggested that both the ‘local’ concentration 
and spatial arrangement of sugar within glycopolymers played a role in preventing protein 
aggregation and retaining enzymatic activity. Similar to low molecular weight sugars, the 
mechanisms by which glycopolymers influence protein structural stability and aggregation are 
still largely unknown, especially in regards to the role of macromolecular features – size, 
macromolecular architecture and dispersity - and the chemical nature of the carbohydrate 
repeating units.  
The present study addresses this important point, with a specific focus on how synthetic 
glycopolymers can affect the conformational and colloidal stability of formulations of 
monoclonal antibodies (mAbs). Here, two different homopolymer libraries were synthesised: 
linear glycopolymers containing a range of carbohydrates - mannose, galactose, arabinose, N-
acetyl glucosamine, lactose or trehalose- in their repeating units, and their corresponding 4-
arm star shaped glycopolymer analogues. More specifically, this work was aimed at 
investigating structure/function relationships for this class of synthetic macromolecules by 
systematically varying polymer structural parameters. The nature of the sugar repeating units 
and the macromolecular architecture were assessed for their influence on protein structural 
stability and aggregation behaviour.  
 
Experimental 
MATERIALS AND METHODS 
Monoclonal antibody. The monoclonal antibody (mAb1) used in this study is a bi-specific 
antibody (IgG1), with a molecular weight of 204 kDa and was provided by MedImmune 
(Cambridge, UK). The mAb has three distinct unfolding transition temperatures (Tm,CH2, Tm,Fab, 
Tm,CH3), with an experimentally determined isoelectric point (pI) of 9.  
 
Equipment. All polymerisation reactions were carried out using standard Schlenk techniques 
under an inert atmosphere of oxygen-free nitrogen, unless otherwise stated. TLC was 
performed using pre-coated silica gel 60 F254 and developed in the solvent systems indicated. 
Compounds were visualized by KMnO4 staining. Merck 60 (230-400 mesh) silica gel was used 
for column chromatography. Molar mass distributions were measured using size exclusion 
chromatography (SEC). 
Size exclusion chromatography - Multi-angle static light scattering (SEC-MALS). SEC-MALS was 
carried out with a Wyatt dawn 8+ 1200 Infinity series in a system equipped with a SEC 
Analytical Column for membrane proteins, TSKgel® Size Exclusion (SW-Type) HPLC Column, 
G3000SWxI, L, 5 µM, 300 Å. Standard Dulbecco’s Phosphate Buffered Saline (DPBS) was used 
as the mobile phase, with a flow rate of 1 mL min-1. Number average molecular weight (Mn) 
and dispersity (Đ) were calculated by a standard calibration method using poly(ethylene glycol) 
narrow standards (Polymer Laboratories, AqGPC). The resulting chromatograms were analysed 
using ASTRA® software, V.6.1.2.84 (Wyatt Tech Corp). 
Nuclear Magnetic Resonance. 1H and 13C Nuclear Magnetic Resonance (NMR) analysis was 
carried out using a Bruker DPX400 UltraShield™ Spectrometer. The spectra were processed 
with MestReNova 6.0.2© 2009 Mestrelab Research S.L. All chemical shifts are reported in ppm 
(δ) relative to tetramethylsilane, referenced to the chemical shifts of residual solvents 
resonances.  
Mass Spectrometry. Mass Spectrometry was carried out using a Micromass LCT KC453 
spectrometer. Data were processed with OpenLynx software. 
Differential Scanning Calorimetry (DSC). Measurements were performed on a Nano DSC (TA 
Instruments, USA), scanning once from 25 to 110 °C at 2 °C/min following an equilibration time 
of 10 min and using a data interval of 5 s; reproducibility was confirmed using water-water 
baseline tests. Protein samples were prepared at a concentration of 1.0 mg mL-1 and filtered 
through of 0.2 µm filter. Lysozyme standards of 3.0 mg mL-1 were measured at start and end 
of the protein samples and verified to yield a single Tm of 60.1 ± 2.0 °C and ΔH of 415 ± 20 
kJ/mol. 900 µL of each protein sample, standard, and blank buffer, were loaded into a 96 well 
plate, the wells sealed with a silicon mat and the plate loaded into the autosampler. 
Thermograms were analysed using TA Instruments software, NanoAnalyze, with the protein 
contribution to the change in molar heat capacity (Cp) determined by subtracting a scan for 
the blank buffer from the protein sample. A baseline correction for each scan before and after 
the endothermic peak was made and the data then fitted to a two-state (scaled) model of 
protein unfolding to calculate the melting temperature (Tm). 
Static light scattering (SLS) and intrinsic fluorescence. SLS and intrinsic fluorescence 
measurements were conducted simultaneously, using an Optim 2 system (Avacta Group plc, 
Thorp Arch Estate, Wetherby, United Kingdom). Data were processed using the standard 
Optim analysis software provided, as per manufacturer's recommendations. Protein 
conformational stability was assessed by measuring the temperature of the onset of melting, 
that is, the mid-point temperature of the three unfolding transitions (Tm,CH2, Tm,Fab, Tm,CH3). This 
was monitored by following the change in intrinsic fluorescence intensity ratio (350/330 nm), 
which occurs as the protein unfolds, due to different tryptophan solvent exposure. SLS at λ = 
266 nm was used as an indicator for colloidal stability, and was used to measure the 
aggregation onset temperature (Tagg), defined as the temperature where a 10% of the total 
change in signal was observed.20  For SLS and intrinsic fluorescence studies, a mAb1 stock 
solution (50 mg mL-1) was diluted to a 2.0 mg mL-1 concentration, in 25 mM histidine buffer, 
pH 6.4.21 The excipients to screen were dissolved in the same buffer at double the 
concentration required in the measurement sample. These solutions were then mixed in a 1:1 
vol:vol ratio, yielding a final protein concentration of 1.0 mg mL -1, at the desired 
mAb1:excipient ratio. Control mAb1 samples without additional excipients were prepared by 
diluting the 2.0 mg mL-1 solution of mAb1 with equal volumes of 25 mM histidine buffer, pH 
6.4. Tagg was automatically determined using the software supplied by the manufacturer. The 
molar ratios were calculated considering the molecular weights of mAb1, mono- and di-
saccharides, and polymer saccharide repeating units. Ratios were therefore calculated based 
on mAb1 vs. concentration of sugar units, either as isolated low molecular weight mono- and 
di-saccharides, or as carbohydrate moieties included within polymer chains. 
All polymers were analysed in an extensive formulation screening, with 9 repeats per polymer 
formulation resulting from three different runs with 3 repeats per run. For every glycopolymer 
or low molecular weight sugars, all excipient: mAb1: ratios were analysed in the same run, 
along with three repeats for mAb1 alone, in the absence of any excipients (controls), to enable 
easier and more accurate comparison of data. Due to mAb1 controls being run for each 
excipient tested, non-stabilised mAb1 was thus analysed for a total of 108 repeats.  
In the SLS and intrinsic fluorescence studies, the samples were heated from 25 to 90 °C using 
1 °C increments, with an equilibration time of 30 s before each point measurement. The 
sample measurements were run in triplicate (vide infra).   
Accelerated stability studies. Accelerated stability studies were carried out at a 50 mg mL-1 
mAb1 concentration, formulated in 25 mM histidine buffer, pH 6.4. The glycopolymers were 
added as solids to 50 mg mL-1 mAb1 solutions to achieve the [mAb1]:[polymer sugar repeating 
units] ratios required. The resulting solutions were transferred to glass vials and stored for the 
required number of weeks at 25 °C (accelerated conditions) and 40 °C (stress conditions), with 
three individual replicate samples per [mAb1]:[polymer sugar repeating units] ratio. At the 
required time point, samples were analysed individually and the mean with standard deviation 
of these readings was reported for each [mAb1]:[polymer sugar repeating units]. Protein 
degradation was assessed at regular time points by Size Exclusion-High Performance Liquid 
Chromatography (SE-HPLC). At time zero samples were run and the area under the curve (AUC) 
of the peak for native mAb1 (here referred to as monomer as a reference to oligomeric or 
aggregated and/or degradation products) was calculated. The degradation of mAb1 was 
assessed via integration of the AUC of the monomer peak in comparison to the integration of 
the AUC of all the peaks appearing in subsequent weeks, as described by Kheddo, et al.22 The 
samples were tested weekly by SE-HPLC, using a Shimadzu HPLC system (LC-20 AP pump), 
equipped with a SPD-M20A UV detector and SIL-20A autosampler. A Tosoh TSKgel column was 
used, with 5 L samples being injected each time, with DPBS as the mobile phase, with UV 
detection at λ = 280 nm. 
Statistics. Statistical analyses were carried out using GraphPad Prism v6. The statistical 
significance of differences between groups was determined using one-way ANOVA, comparing 
the values of the mAb alone with mAb runs in the presence of excipients. Comparisons were 
considered non-significant, * p < 0.05, or ** p < 0.01. 
Results and discussion 
Synthesis of glycopolymers. In this work, sugar-based polymers were synthesised by post-
polymerisation modification of functional polymers with a range of complementarily reactive 
carbohydrates, as described by Ladmiral et al,23 to create two libraries of glycopolymers with 
different compositions and topology.  Linear- or star-shaped four-arm architectures were 
selected with a view to investigate the effect of the polymer architecture on protein stability 
in solution. By generating all materials from common macromolecular precursors, all polymers 
within each library have identical degree of polymerisation (DP, that is, the number of polymer 
repeating units) and molecular weight dispersity, and only vary for the nature of the pendant 
sugar units. This allowed us to isolate and deconvolute the effect of a single structural variable 
- the nature of the carbohydrate repeating units – on protein stabilisation. To prepare the 
required glycopolymers, the low molecular weight sugar (mono- or disaccharide) employed in 
this study were modified to introduce alkylazido chemical ’handles’ in their molecular 
structure, to chemically graft these modified saccharides to preformed poly(propargyl 
methacrylate) polymer precursors, by ‘click‘ CuAAC reaction23 (Scheme 1).  
For mannose, galactose and arabinose, the monosaccharide starting materials were 
suspended in an excess of 2-bromoethanol and heated at 90 °C in the presence of Amberlite 
120H acid catalyst.24 The resulting 2’-bromoethyl glycoside intermediates were then treated 
with NaN3 in DMF to give the sugar azides required for polymer conjugation. A similar protocol 
was utilised for the synthesis of 2’-azidoethyl N-acetyl glucosamine, with the difference that 
HBr generated in situ with acetyl bromide was utilised as the catalyst to generate the required 
2’-bromoethyl glycoside intermediate (8d). This procedure – direct conversion of sugars into 
their corresponding alkyl bromide glycosides followed by treatment with NaN3 – was found to 
be particularly suited for the functionalization of monosaccharides, which was achieved in only 
two steps from commercially available carbohydrates, and did not require 
protection/deprotection of the sugar hydroxyl groups.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of the mannose, arabinose, galactose, N-acetyl glucosamine, lactose, and 
trehalose azides employed in this study as precursors to the required linear and star glycopolymers. 
Reagents and conditions: i. 2-bromoethanol, Amberlite H120, 90 °C, 2.5 h; ii. NaN3, DMF, 80 °C, 24 h; 
iii. 2-bromoethanol, acetyl bromide; iv. NaN3, DMF, 50 °C, 20 h; v. I2, Ac2O; vi. BF3·OEt2, 2-
bromoethanol; 2-bromoethanol; CH2Cl2; vii. NaN3, DMF, 50 °C, 20 h, viii. CH3ONa, CH3OH; ix. 
chloroacetyl chloride, 2,4,6-collidine, DMF; NaN3, DMF. Letter labels (a: mannose, b: galactose, c: 
arabinose, d: N-acetyl glucosamine, e. lactose, f: trehalose) are included in the code name for final 
sugar azides to facilitate the identification of their corresponding final glycopolymers (see also Table 
1). 
Application of this general protocol to the synthesis of lactose azide resulted in undesired 
transacetalyzation side-process, where 2-bromoethyl gluco- and galactopyranosides were 
formed due to cleavage of the β-1→4 glycosidic linkage between glucose and galactose in the 
lactose molecule. An alternative route was then identified, where lactose was first 
peracetylated with acetic anhydride and I2 as the catalyst,25 followed by treatment with 2-
bromoethanol and BF3.OEt2, to introduce the required alkylhalide functionality. Subsequent 
reaction with NaN3 followed by deprotection with CH3ONa/CH3OH, afforded the desired 
lactose azide (9e).   
Trehalose consists of two glucose units connected via an α,α-1,1-glycosidic bond, hence the 
general approach utilised to synthesize the other sugar azides - introducing an azide-containing 
O-alkyl glycoside group - was not applicable, as it would have resulted in the cleavage of the 
linkage holding together the two glucopyranoside residues. Thus, an alternative strategy was 
utilised that involved reaction of D-(+)-trehalose dehydrate with chloroacetyl chloride in DMF 
using 2,4,6-collidine as a base. This was carried out at -50 °C to favour reaction of the sugar 
primary hydroxyl groups over the more hindered secondary ones. Treatment of the reaction 
crude product – consisting of a statistical distribution of trehalose starting material, and mono 
and bis sugar alpha-chloroacetates - with sodium azide in DMF followed by flash 
chromatography on SiO2 afforded the desired trehalose monoazide (10f).  
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of linear (13a-f) and star (16a-f) glycopolymers. Top: clickable linear (13) and star 
(16) poly(propargyl methacrylate) precursors; and ‘click’ synthesis of the required glycopolymers 
(linear 13a-f, and star 16a-f). a: mannose, b: galactose, c: arabinose, d: N-acetyl glucosamine, e: 
lactose, f: trehalose. 
The synthesis of the required functionalizable polymer precursors and all required 
intermediates was carried out following a general strategy previously reported by  Haddleton 
and ourselves and subsequently utilised in a number of studies24, 26-31 for quantitative polymer 
functionalization with sugar azides.23 Linear and 4-arm star poly(propargyl methacrylate)s 
were synthesized via ATRP, using trimethylsilyl-propargyl methacrylate monomer and mono- 
and tetravalent initiators prepared from benzyl alcohol and pentaerithrol, respectively 
(Scheme 2).23 
Polymerisations were carried out using the required initiator and N-(ethyl)-2-
pyridinmethanimide / Cu(I)Br catalytic system, in toluene at 70 °C. The resulting polymers were 
deprotected by removing the TMS group with tetrabutylammonium fluoride (TBAF) and acetic 
acid, thus affording the desired clickable linear (DP 66, ĐSEC 1.29) and star (DP 77, ĐSEC 1.23) 
polymers. 
Finally, the polymers were functionalised via Copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) 
in DMF in the presence of the required sugar azides, using Cu(I)Br/Bipy as the catalyst. Quantitative 
polymer functionalisation was confirmed by the complete disappearance of the propargyl 
methacrylate repeating unit signals in the 1H NMR spectra of the final, linear (13a-f) and 4-arm star 
(16a-f) glycopolymers (Table 1). 
Table 1. Glycopolymers synthesized and utilised in this work and their macromolecular features. 
Polymer 
codea 
Architecture Sugar DPb Mnc 
(kDa) 
Đc 
13a Linear Mannose 66 23.9 1.22 
13b Linear Galactose 66 22.5 1.23 
13c Linear Arabinose 66 23.5 1.26 
13d Linear NAc 
Glucosamine 
66 27.0 1.29 
13e Linear Lactose  66 25.5 1.25 
13f Linear Trehalose 66 37.6 1.18 
16a Star Mannose 77 27.2 1.25 
16b Star Galactose 77 24.5 1.28 
16c Star Arabinose 77 20.5 1.23 
16d Star NAc 
Glucosamine 
77 29.5 1.29 
16e Star Lactose  77 42.6 1.29 
16f Star Trehalose 77 55.9 1.17 
a Polymer code as per numbering in Schemes 1 and 2. b Degree of polymerisation (DP) calculated by 1H-NMR of the 
glycopolymers by comparing the area of the signals of the pendant propargyl ester repeating groups to those from the 
polymerisation initiators.  c Mn and Đ determined by SEC in DPBS (see Methods). 
Design of stability studies of mAb1. Amongst sugars investigated in this study, trehalose is a 
commonly used formulation excipient, due to its demonstrated ability to stabilise 
conformational and solution colloidal properties of antibodies.32,33, 34 In contrast, 
monosaccharides mannose, galactose, arabinose and N-acetyl glucosamine, or di-saccharide 
lactose, are not frequently utilised.35 at least in part due to the hemiacetal ends of these sugars 
being reactive towards protein amino groups, through a series of side-processes that include 
formation of imines and Maillard reactions.36,37,38,39 In the present study, this issue was 
circumvented through the use of a stable acetal linker connecting the polymer backbone to 
the sugar pendant residues, which made the glycopolymers virtually non-reactive against 
amines. We tested the effects of polymer architecture (linear vs. 4-arms star) and nature of 
the repeating sugar units on model antibody conformational and colloidal stability.  In addition, 
we also investigated the effects of concentration and polymer:mAb1 ratios (by varying the 
[polymer sugar repeating units]:[mAb1molar ratio) on these parameters, as the concentration 
of polyhydroxylated excipient is known to affect the stability of monoclonal antibodies in 
solution. 40,41,42  
 
The effect of sugars and glycopolymers on mAb1 conformational stability. Initial experiments 
focused on mAb1 in the absence of excipients, which showed distinct transitions for the 
unfolding of its structural domains by DSC: Tm = 69.46 °C for CH2, Tm = 78.70 °C for Fab and Tm 
= 85.05 °C for CH3 (Figure S46), where CH2 and CH3 are constant regions of the heavy chain of 
the Fc (fragment crystallisation), and Fab is the antigen-binding fragment.  In this study  
intrinsic fluorescence and light scattering measurements were carried out simultaneously, to 
investigate protein conformational stability and solution aggregation, respectively, on the 
same samples and experimental conditions. Conformational stability of mAb1 was assessed 
from its intrinsic fluorescence,.20 as upon protein unfolding tryptophan (Trp) emission (λmax) 
undergoes a bathochromic shift, typically from ~335 to 355 nm, which occurs when, upon heat-
induced denaturation, Trp residues buried within hydrophobic protein domains become 
exposed to a more polar aqueous environment,.20,43,44 It should be noted that the intrinsic 
fluorescence measurements reported in Figure 1 (values for mAb1 alone) are in agreement 
with DSC data for the mAb1 unfolding transitions (Figure S46 and Table S1). Tm indicates the 
mid-point temperature of the transition from native to a fully unfolded conformation for mAb1 
in solution, and an increase in Tm in the presence of an excipient is considered to be indicative 
of enhanced conformational stability.20,40,41  
Changes in mAb1 unfolding transition temperatures in the presence of low molecular weight 
sugars and glycopolymers  ranged from 0.1 °C to 3.22 °C (Figure 1). In previous studies 
differences of ± 0.2 °C have been reported, and utilised to discriminate between different 
formulations.45  
 
Amongst low molecular weight mono-and di-saccharide excipients, trehalose produced an 
overall stabilising effect on mAb unfolding, as judged from an increase of Tm for all three mAb 
domains (Figure 1); which is in agreement with previous studies.33, 34,46,47 Similarly, the 
stabilising profile of lactose was in agreement with reports for other disaccharides, such as 
sucrose41, 48. For other tested sugars, increases in Tm,CH2 and Tm,Fab were observed; the latter 
being particularly prominent for galactose and arabinose. The effect on Tm of CH3 domain was 
found to be more dependent on the nature of the sugar utilised, with, in general, d estabilising 
effects of monosaccharides, particularly galactose, and stabilisingstabilisation provided by 
disaccharides, particularly trehalose. Since reducing monosaccharides are not commonly used 
to stabilise protein formulations, comparative data are not easily available.  
For the linear and star glycopolymers (13a-f) and (16a-f), respectively, and at low mAb1 
concentration (1.0 mg mL-1), the most prominent and consistent effect on temperature-
induced stress was a general decrease in Tm of CH2 domain, regardless of molecular topology, 
chemistry of the sugar repeating units, or sugar:protein molar ratio. This general effect was in 
clear contrast to the predominantly stabilising effect seen for corresponding mono- and di-
saccharides. Interestingly, decreased Tm,CH2 values are pronounced for monosaccharide-based 
linear- and star-glycopolymers (e.g. mannose and galactose), very low for disaccharide lactose, 
but pronounced for disaccharide trehalose.  
The effect of glycopolymers on Tm,Fab and Tm,CH3 of mAb1 was less consistent, with unclear 
patterns. It is however noticeable that glycopolymers did not show the general stabilisation of 
the Fab domain seen for the corresponding mono- and di-saccharides. Comparisons between 
individual sugars and the corresponding glycopolymers revealed that, for instance, arabinose 
monosaccharide caused a prominent increase in TmFab and small effect on Tm,CH3, whilst linear 
arabinose glycopolymer (13c) produced a prominent effect on lowering Tm,CH3 and a small 
effect on lowering Tm,Fab. 
Arabinose-based polymers behaved differently than monosaccharide mannose- and galactose-
glycopolymers, whilst N-acetyl glucosamine-star polymer (16d) had a pronounced destabilising 
effect on the Fab domain. 
This might suggest that, amongst mono-saccharide-based glycopolymers, the size and nature 
of the sugar repeating units may be an influencing factor in affecting the unfolding 
temperatures of mAb1 domains. For di-saccharide based glycopolymers,an increase in Tm,Fab 
induced by lactose linear and 4-arms (13e and 16e), and a decrease elicited by trehalose linear 
and 4-arms glycopolymers (13f and higher ratios of 16f) was observed; a result that at this 
stage is difficult to rationalise. 
 
Figure 1. Change in Tm values obtained from intrinsic fluorescence readings of CH2, Fab, and 
CH3 mAb1 domains in the presence of low molecular weight mono/di-saccharides, and linear 
(13a-f) and star (16a-f) glycopolymers, relative to mAb1 in histidine buffer only (Tm,CH2 = 69.46 
°C, Tm,Fab = 78.70 °C, Tm,CH3 = 85.05 °C), as measured by Optim 2 instrument. In all samples 
[mAb1] = 1.0 mg mL-1, in 25 mM histidine buffer, pH 6.4. Statistical significance, * = p < 0.05. 
Variations in sugar:protein molar ratio did not result in clear trends on modulation of Tm of 
CH2, Fab, and CH3 domains, with the exception of the trehalose-based star polymer (16f), 
which produced a stabilising effect at lower molar ratios (1:1 and 100:1) and a destabilising 
effect at higher ratios (200:1 and 300:1) (Figure 1). 
Published work on structural stability of IgGs in the presence of different excipients suggests 
that the CH2 domain, the most unstable in response to thermal and chemical insults, may 
determine the overall physical stability of mAbs.41,49 Applied to the present study, the overall 
decrease of the Tm,CH2 induced by all the tested glycopolymers regardless of composition or 
molecular architecture might therefore  suggest that under the exerimental conditions 
investigated, these glycopolymers mostly exert an overall destabilising effect on the mAb. 
 
The effect of sugars and glycopolymers on mAb1 thermally induced aggregation. SLS analysis 
provided an insight into the colloidal stability of mAb1 samples towards aggregation (Figure 
2). It has been proposed that, upon unfolding, non-native protein conformations expose 
hydrophobic ‘patches’ which can initiate self-association through non-reversible and non-
specific assembly pathways, leading to the formation of soluble and insoluble aggregates.50 
Tagg reflects the temperature at which a noticeable change in light scattering of the protein 
solution is measured, as a consequence of the presence of insoluble aggregates.20 Values of 
Tagg shown here represent the temperature where a 10% of the total change in signal is 
observed. 
Simultaneous monitoring of both unfolding (Figure 1) and protein aggregation (Figure 2) 
enabled us to assess the effects of the glycopolymers on unfolding (Tm) and aggregation (Tagg) 
recorded for the same mAb1 samples. It should be noted that Tm and Tagg values are not 
expected to overlap, as they are related to distinct structural and kinetic phenomena.51  
Aggregation temperatures (Tagg) lower than Tm have been described for a number of proteins,52 
and could be attributed to thermally induced self-association prior to denaturation, which in 
turn may lead to subsequent denaturation. In addition, Tm is defined as the mid-point of 
unfolding transition, thus it does not accurately define the onset of the process. In systems 
where a relatively low proportion of unfolded proteins can initiate the formation of 
aggregates, Tagg < Tm may be observed.  
Under the stress conditions employed in this work, Tagg of mAb1 alone (60.6 °C) was found to 
be lower than Tm values of CH2, Fab and CH3 domains (Figure 1), indicating the antibody 
propensity to initiate aggregation at low levels of molecular unfolding.  
 
Figure 2. Change in mAb1 Tagg in the presence of low molecular weight mono- and di-saccharides, and 
linear (13a-f) and star (16a-f) glycopolymers, relative to mAb1 in histidine buffer alone (Tagg = 60.64 
°C), as measured by SLS. In all samples [mAb1] = 1.0 mg mL-1, in 25 mM histidine buffer, pH 6.4. 
Statistical significance, ** = p < 0.01. 
A more detailed inspection of SLS profiles for the mAb1 alone, and its sugar and glycopolymer 
formulations (representative examples shown in Figure S47) revealed a two-step aggregation 
process with a small increase just above 60 °C and an incremental, larger increase at 
temperatures above ~ 70 °C. It should be noted that trehalose glycopolymers showed a less 
pronounced initial step compared to the other glycopolymers(Figure S47), resulting in higher 
estimated Tagg values. In general, the addition of mono- or di-saccharides to mAb1 solutions 
over all concentrations ratios tested did not result in a significant modulation of the antibody’s 
Tagg over all concentrations tested (Figure 2). In contrast, the linear- and star-glycopolymers 
based on monosaccharides mannose and galactose appeared to promote thermally induced 
mAb1 aggregation, resulting in a decrease in Tagg of up to 3 °C. The opposite  was observed for 
di-saccharide-based glycopolymers, 
where 4-arm lactose and trehalose glycopolymers, as well as the linear trehalose glycopolymer 
at specific concentrations, generally raised the Tagg of mAb1 (although the Tagg values estimated 
for trehalose polymers need to be viewed with some caution, as discussed above). 
In terms of sugar:mAb ratios,  the linear glycopolymers , induced a more pronounced decrease 
in the Tagg at the higher ratios with the exception of the N-acetyl glucosamine (13d) polymer 
at the highest ratio. In formulations containing trehalose linear glycopolymer (13f), a stabilising 
effect was observed at lower concentrations (1:1 and 100:1 molar ratios) and an increasing 
destabilising effect at higher concentrations (200:1 and 300:1), similar to the other linear 
polymer excipients.. Such concentration-dependent effect was found to be less pronounced 
for the 4-arms star library, with exception of the galactose polymer (16b).  
From the protein conformation stability and aggregation studies undertaken in this work, some 
initial structure-function correlations can be established for the glycopolymer-containing 
formulations. In general, glycopolymers based on monosaccharide repeating units in linear or 
4-arm star configurations in general induced a decrease in the Tm of CH2 and Fab domains of 
mAb1 (Tm,CH2 and Tm,Fab) which occurred along with a decrease in Tagg. For disaccharides, 
lactose-based glycopolymers did not show a significant destabilising effect on the CH2 domain 
(Tm,CH2), while increasing stabilisation of the Fab domain (Tm,Fab). This destabilising effect may 
have resulted in the increase of Tagg observed for the star glycopolymer (16e) but not for the 
linear (13e). Interestingly, trehalose based polymers (13e) and (13f) appeared to show 
concentration-dependent effect in influencing both Tm and Tagg of mAb1, with stabilising effects 
at lower concentrations, and an increasingly destabilising effect at higher concentrations.  
In the context of modulation of antibody structural stability, properties such as the ability to 
form hydrogen bonding networks between individual sugar units and sugar-water have been 
shown to be specific to the chemistry of the sugar utilised, with consequent distinct effects on 
protein stability.53 This bonding landscape is likely to vary for the different sugars incorporated 
in our glycopolymers, and consequently one could expect distinctive interactions with protein 
surface that might induce divergent modulation of aggregation behaviour. 
Accelerated stability studies. To assess the effect of glycopolymers on long term storage 
stability of mAb1, accelerated stability studies of highly concentrated solutions (50 mg mL -1) 
were undertaken. In these experiments, glycopolymers with both linear and 4-arm star 
architectures, mannose, (13a) and (16a), lactose, (13e) and (16e), and trehalose, (13f) and 
(16f) were selected. Mannose-glycopolymers were utilised as examples of polymers with 
monosaccharide repeating unit which showed clear destabilising effect on mAb1 - i.e. 
consistently decreased Tm,CH2 and Tagg (Figures 1 and 2). 
Both lactose- and trehalose-based disaccharide-glycopolymers were investigated due to their rather 
different behaviour in previous conformational and colloidal stability experiments (Figures 1 and 2). 
Trehalose as low molecular weight disaccharide displayed a clear positive effect on mAb1 
conformational stability (increasing Tm values), which was lost as trehalose linear or star 
glycopolymers. In addition, colloidal stability SLS profiles for trehalose based  were somewhat altered, 
compared to other glycopolymers(Figure S47). Lactose glycopolymers were selected as they induced 
less well-defined trends in the protein conformation and colloidal stability studies. 
Figure 3. Physical stability of mAb1 (50 mg mL-1 in 25 mM histidine buffer, pH 6.4) vs time, in solutions 
formulated with linear and star glycopolymers of mannose (13a and 16a), lactose (13e and 16e), and 
trehalose (13f and 16f), at different [sugar repeating units]:[mAb1] molar ratios, at 25 °C (left, 
accelerated conditions) and 40 °C (right, stress conditions). Residual native mAb1 (monomer) % in 
solution was determined via SE-HPLC using DPBS as the mobile phase, and calculated via integration 
of the AUC of the mAb1 and peaks of degradation products. 
In these experiments, the decrease in concentration of mAb native protein in solution - 
referred to as mAb1 monomer to differentiate it from its oligomeric aggregation products 
formed over time - was monitored over seven weeks. mAb1 solution at 50 mg mL-1 was used 
in all formulations tested in this part of the study to mimic the high concentrations of antibody 
solutions often required for pharmaceutical products. Additionally, the use of a high 
concentration solution of mAb1 also allowed for better assessment of the loss of mAb1 
monomer.54 As in the previous experiments, the glycopolymers were added in four different 
sugar:mAb1 molar ratios.  
The resulting stability profiles indicate that, in general, increasing sugar:protein molar ratio 
resulted in a decrease in native mAb1 (monomer) content over time, for all formulations 
tested, at both 25 and 40 °C (Figure 3). Interestingly, mannose glycopolymers (13a) and (16a), 
which showed clear destabilising effect in protein conformation and stability tests, appeared 
to produce relatively modest destabilising effect on long term stability of the mAb1 solutions, 
even at 300:1 sugar:mAb1 ratios, i.e. concentrated glycopolymer solutions. This is in contrast 
to mAb1 solutions containing trehalose glycopolymers (13a) and (16a). Stabilization of 
antibody unfolding, i.e increased Tm and Tagg was seen at lower sugar:mAb1 ratio (100:1), whilst 
at the higher mAb1 concentration utilised in these accelerated stability studies (50 mg mL -1) 
both linear and star trehalose glycopolymers induced visible precipitation from week two, as 
confirmed by a decrease of the mAb1 monomer content over time observed by SE-HPLC 
analysis, already at 100:1 molar ratio. Formulations containing mannose and lactose linear or 
star glycopolymers, were visually free of precipitated material throughout the seven-week 
experiment.   
It is commonly accepted that hydrophilic polymers can increase the conformational stability of 
mAbs by the excluded volume effect and/or preferential exclusion mechanisms.41 The 
glycopolymers should, therefore, exclude themselves from the protein surface, forcing the 
protein to stay in a preferential hydrated state, adopting more compact conformations, which 
often correspond (or are closely related) to the protein native conformation.24,55 However, 
such an exclusion of excipients from the vicinity of protein macromolecules can sometimes 
result in microenvironments with higher protein local concentration, which favours protein-
protein interactions, and may eventually lead to protein aggregation. This effect is often more 
pronounced at high protein concentrations,56,57 such as 50 mg mL-1 utilised for this study. 
Accordingly, particular glycopolymer compositions or molecule architectures lead to different 
macromolecular crowding effects, hence resulting in mAb1 aggregation to a different extents. 
Interestingly, SEC analysis of trehalose glycopolymers (13f) and (16f) in aqueous conditions 
showed that, whilst possessing a narrow dispersity Ð (1.18 for linear (13f) and 1.17 for star 
(16f) which are slightly narrower than that of the other glycopolymers), these polymers had 
hydrodynamic volumes higher than expected when compared to poly(ethylene glycol) narrow 
standards used as SEC calibrants, a phenomenon that is in line with a previous report by 
Maynard and co-workers for styrene-based trehalose polymers.19 In our study we found that 
trehalose glycopolymers (13f) and (16f) had a molecular weight slightly higher than that of 
disaccharide lactose (13e) and (16e) (37.6 vs. 25.5 kDa for linear, 55.9 vs. 42.6 kDa for star 
glycopolymers, for trehalose and lactose, respectively; Table 1). Although studies on the 
detailed mechanism of these protein aggregation phenomena are currently on-going, the 
higher hydrodynamic volume of trehalose glycopolymers might explain the distinctive 
behaviour of solutions containing these glycopolymers in the accelerated stability studies. 
These results are in agreement with previous work by Miura and co-workers, who showed that 
the fibrillation of Aβ(1-40) was favoured for polyacrylamide-based linear glycopolymers with 
trehalose moieties present at each polymer repeating unit - thus structurally analogous to 
(13f)..58 Interestingly, these authors also found that when their trehalose monomer was 
copolymerised with an excess of acrylamide, a significantly smaller, hydrophilic monomer, the 
resulting materials could reduce fibrillation of Aβ(1-40). This trend could be ascribed, at least 
in part, to the different macromolecular crowding provided by trehalose homo- and co-
polymers investigated in their work. 
  
Simultaneous study of the conformational and colloidal stability of protein formulations are of 
great importance to understand the phenomena underpinning the lack of long-term stability 
of a number of potential mAb biotherapeutics. The stability of the CH2 domain appeared to be 
governing the overall behaviour of mAb1; the glycopolymers solutions that decreased Tm,CH2 
resulted in decreased mAb1 monomer content, i.e. presence of antibody aggregation in the 
accelerated stability studies. For the latter, trehalose polymers overall produced the most 
marked effect on the colloidal stability of mAb1, with visible precipitation observed from as 
early as week two.  Although the distinctiveness of the colloidal stability profile of the trehalose 
polymers (Tagg, Figure S47) was noticed during initial characterisation stage, it was only during 
the accelerated stability studies that the extent of mAb1 aggregation was appreciated, due to 
the visible precipitates.  
Overall, the trend of decreased conformational and colloidal stability of mAb1, assessed from 
intrinsic fluorescence and static light scattering measurements (Tm,CH2 and Tagg) of thermally 
stressed formulations, appears to be generally in line the trends from accelerated stability 
studies, despite high antibody concentrations in the latter, therefore suggesting that screening 
of Tm and Tagg could be employed to predict the stability of selected mAbs.  
Conclusions 
Two libraries of well-defined glycopolymers with linear and four-arm star architectures were 
successfully synthesised via ATRP and post polymerisation modification via ‘click chemistry’. Applied 
as solution excipients to a model antibody solution, these glycopolymers modulated both the 
conformational and colloidal stability of a model monoclonal antibody, mAb1. Initial structure-
function relationships for these macromolecular excipients were identified, with effects dependent 
on the nature of sugar monomer, concentration in solution and polymer architecture. The 
glycopolymers mostly decreased the stability of formulations of the model antibody at lower 
concentrations, opposite to what was observed to the corresponding low molecular weight sugars. 
Moreover, the polymers often destabilised the protein in solution to a greater extent at higher 
concentrations. Interestingly, this induction of mAb1 aggregation was particularly pronounced for 
trehalose-based glycopolymers, especially at their higher concentrations, and was only appreciated in 
long term stability studies. It is notable that effects of low molecular weight sugar excipients cannot 
be extrapolated to effects of corresponding glycopolymers and that often at higher concentrations of 
glycopolymers in solution induction of antibody unfolding and/or aggregation, rather than 
stabilisation to aggregation, prevails. More studies of the mechanisms involved are still required to 
understand this phenomenon and are currently being undertaken. This study also suggests that the 
use of glycopolymers as excipients of protein liquid formulations is very much dependent on the 
physico-chemical characteristics of these macromolecular materials (and possibly on the nature of the 
protein therapeutic of choice), hence their suitability as stabilisers for protein liquid formulations 
needs to be evaluated on a case by case basis. 
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